Skip to main
JBIO

JBIO Earnings Dates & Reports

JBIO Most Recent Earnings

Report Date
Period EndingQ1 2026
Est. EPS-$0.49
Actual EPS-$0.57
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

JBIO Earnings per Share (EPS) History

Signup for full access
Browse free

JBIO Latest Earnings

The value each JBIO share was expected to gain vs. the value each share gained.

JBIO reported its most recent earnings on for Q1 2026, posting earnings per share (EPS) of -$0.57. This exceeded analysts' expectations of -$0.49 by 16.33%, marking a Miss.

For comparison, Aerovate Therapeutics Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.58.

JBIO Earnings History

Earnings
Est. EPSActual EPSSurprise
Q2 2026
-$0.58
Q1 2026
-$0.49-$0.57+16.33%
Q4 2025
-$0.46-$0.11-76.09%
Q3 2025
-$0.63-$0.48-23.81%
Q2 2025
-$0.43-$0.86+100.00%

JBIO Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Aerovate Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

JBIO Earnings FAQs

JBIO last reported earnings on May 7, 2026 for Q1 2026, posting an EPS of -$0.57, which Miss the estimate of -$0.49 by 16.33%.

For Q1 2026, JBIO reported an EPS of -$0.57, missing analysts' estimate of -$0.49 by 16.33%.

For Q1 2026, JBIO Miss expectations with an actual EPS of -$0.57 vs. an estimated EPS of -$0.49.

Following the last earnings report on May 7, 2026, JBIO's stock price moved — from — to —.

The next JBIO earnings call is scheduled for Aug. 12, 2026, where executives will discuss financial results and outlook.

Aerovate Therapeutics Inc (JBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.